Serum brain-derived neurotrophic factor levels and cocaine-induced transient psychotic symptoms

Neuropsychobiology

Volumn 68, Issue 3, 2013, Pages 146-155

  Corominas Roso, Margarida ^a   Roncero, Carlos ^a,b,c   Eiroa Orosa, Francisco Jose ^a,b   Ribasés, Marta ^a,d   Barral, Carmen ^a,b   Daigre, Constanza ^c   Martínez Luna, Nieves ^c   Sánchez Mora, Cristina ^d   Ramos Quiroga, Josep Antoni ^a,b   Casas, Miguel ^a,b,c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c University Hospital Vall d'Hebron ASPB   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Addiction; Brain derived neurotrophic factor; Cocaine; Cocaine induced psychosis

Indexed keywords

BIPERIDEN; BRAIN DERIVED NEUROTROPHIC FACTOR; CAFFEINE; COCAINE; CORTICOSTEROID; PLACEBO;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DEMOGRAPHY; DEPRESSION; DETOXIFICATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA; WITHDRAWAL SYNDROME; BLOOD LEVEL; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL (TOPIC); COCAINE SELECTIVE SEVERITY ASSESSMENT; COCAINE-INDUCED PSYCHOSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DETOXIFICATION; DRUG USE; STATISTICAL ANALYSIS;

ADULT; BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; COCAINE-RELATED DISORDERS; FEMALE; HUMANS; MALE; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 84888233138     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000353259     Document Type: Article

References (88)

1. Brady KT, Lydiard RB, Malcolm R, Ballenger JC: Cocaine-induced psychosis. J Clin Psychiatry 1991; 52: 509-512.
2. Roncero C, Daigre C, Gonzalvo B, Valero S, Castells X, Grau-López L, et al: Risk factors for cocaine-induced psychosis in cocaine-dependent patients. Eur Psychiatry 2013; 28: 141-146.
3. Johns LC, Van Os J: The continuity of psychotic experiences in the general population. Clin Psychol Rev 2001; 21: 1125-1141.
4. Kelleher I, Cannon M: Psychotic-like experiences in the general population: characterizing a high-risk group for psychosis. Psychol Med 2011; 41: 1-6.
5. Vorspan F, Bloch V, Brousse G, Bellais L, Gascon J, Lépine J-P: Prospective assessment of transient cocaine-induced psychotic symptoms in a clinical setting. Am J Addict 2011; 20: 535-537.
6. Floyd AG, Boutros NN, Struve FA, Wolf E, Oliwa GM: Risk factors for experiencing psychosis during cocaine use: a preliminary report. J Psychiatr Res 2006; 40: 178-182.
7. Kalayasiri R, Kranzler HR, Weiss R, Brady K, Gueorguieva R, Panhuysen C, et al: Risk factors for cocaine-induced paranoia in cocainedependent sibling pairs. Drug Alcohol Depend 2006; 84: 77-84.
8. Satel SL, Edell WS: Cocaine-induced paranoia and psychosis proneness. Am J Psychiatry 1991; 148: 1708-1711.
9. Manschreck TC, Laughery JA, Weisstein CC, Allen D, Humblestone B, Neville M, et al: Characteristics of freebase cocaine psychosis. Yale J Biol Med 1988; 61: 115-122.
10. Karila L, Petit A, Phan O, Reynaud M: Cocaine-induced psychotic disorders: a review (in French). Rev Med Liege 2010; 65: 623-627.
11. Caton CL, Samet S, Hasin DS: When acutestage psychosis and substance use co-occur: differentiating substance-induced and primary psychotic disorders. J Psychiatr Pract 2000; 6: 256-266.
12. Raballo A, Nelson B, Thompson A, Yung A: The comprehensive assessment of at-risk mental states: from mapping the onset to mapping the structure. Schizophr Res 2011; 127: 107-114.
13. Ramirez N, Arranz B, Salavert J, Alvarez E, Corripio I, Duenas RM, et al: Predictors of schizophrenia in patients with a first episode of psychosis. Psychiatry Res 2010; 175: 11-14.
14. Cubells JF, Kranzler HR, McCance-Katz E, Anderson GM, Malison RT, Price LH, et al: A haplotype at the DBH locus, associated with low plasma dopamine β-hydroxylase activity, also associates with cocaine-induced paranoia. Mol Psychiatry 2000; 5: 56-63.
15. Kalayasiri R, Sughondhabirom A, Gueorguieva R, Coric V, Lynch WJ, Lappalainen J, et al: Dopamine β-hydroxylase gene (DβH) -1021C->T influences self-reported paranoia during cocaine self-administration. Biol Psychiatry 2007; 61: 1310-1313.
16. Gabel S, Stadler J, Bjorn J, Shindledecker R: Homovanillic acid and dopamine-β- hydroxylase in male youth: relationships with paternal substance abuse and antisocial behavior. Am J Drug Alcohol Abuse 1995; 21: 363-378.
17. Hess C, Reif A, Strobel A, Boreatti-Hummer A, Heine M, Lesch K-P, et al: A functional dopamine-β-hydroxylase gene promoter polymorphism is associated with impulsive personality styles, but not with affective disorders. J Neural Transm 2009; 116: 121-130.
18. Altar CA, Fritsche M, Lindsay RM: Cell body infusions of brain-derived neurotrophic factor increase forebrain dopamine release and serotonin metabolism determined with in vivo microdialysis. Adv Pharmacol 1998; 42: 915-921.
19. Narita M, Aoki K, Takagi M, Yajima Y, Suzuki T: Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. Neuroscience 2003; 119: 767-775.
20. Cheng B, Mattson MP: NT-3 and BDNF protect CNS neurons against metabolic/excitotoxic insults. Brain Res 1994; 640: 56-67.
21. Ghosh A, Carnahan J, Greenberg ME: Requirement for BDNF in activity-dependent survival of cortical neurons. Science 1994; 263: 1618-1623.
22. McAllister AK, Katz LC, Lo DC: Neurotrophin regulation of cortical dendritic growth requires activity. Neuron 1996; 17: 1057-1064.
23. Ikeda Y, Yahata N, Ito I, Nagano M, Toyota T, Yoshikawa T, et al: Low serum levels of brainderived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia. Schizophr Res 2008; 101: 58-66.
24. Pirildar S, Gönül AS, Taneli F, Akdeniz F: Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 709-713.
25. Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE: Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003; 8: 592-610.
26. Xiu MH, Hui L, Dang YF, Hou T De, Zhang CX, Zheng YL, et al: Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1508-1512.
27. Zhang XY, Zhou DF, Wu GY, Cao LY, Tan YL, Haile CN, et al: BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology 2008; 33: 2200-2205.
28. Buckley PF, Pillai A, Evans D, Stirewalt E, Mahadik S: Brain-derived neurotropic factor in first-episode psychosis. Schizophr Res 2007; 91: 1-5.
29. Rizos EN, Rontos I, Laskos E, Arsenis G, Michalopoulou PG, Vasilopoulos D, et al: Investigation of serum BDNF levels in drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1308-1311.
30. Zhang XY, Liang J, Chen DC, Xiu MH, Yang F De, Kosten TA, et al: Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacology 2012; 222: 277-284.
31. Vinogradov S, Fisher M, Holland C, Shelly W, Wolkowitz O, Mellon SH: Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol Psychiatry 2009; 66: 549-553.
32. Jindal RD, Pillai AK, Mahadik SP, Eklund K, Montrose DM, Keshavan MS: Decreased BDNF in patients with antipsychotic naive first episode schizophrenia. Schizophr Res 2010; 119: 47-51.
33. Mondelli V, Cattaneo A, Belvederi Murri M, Di Forti M, Handley R, Hepgul N, et al: Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J Clin Psychiatry 2011; 72: 1677-1684.
34. Pillai A, Kale A, Joshi S, Naphade N, Raju MSVK, Nasrallah H, et al: Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol 2010; 13: 535-539.
35. Petryshen TL, Sabeti PC, Aldinger KA, Fry B, Fan JB, Schaffner SF, et al: Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol Psychiatry 2010; 15: 810-815.
36. Chen Z-Y, Patel PD, Sant G, Meng C-X, Teng KK, Hempstead BL, et al: Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activitydependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 2004; 24: 4401-4411.
37. Lang UE, Hellweg R, Sander T, Gallinat J: The Met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations. Mol Psychiatry 2009; 14: 120-122.
38. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, et al: Brain-derived neurotrophic factor Val66Met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 2003; 23: 6690-6694.
39. Simons CJP, Wichers M, Derom C, Thiery E, Myin-Germeys I, Krabbendam L, et al: Subtle gene-environment interactions driving paranoia in daily life. Genes Brain Behav 2009; 8: 5-12.
40. Alemany S, Arias B, Aguilera M, Villa H, Moya J, Ibáñez MI, et al: Childhood abuse, the BDNF-Val66Met polymorphism and adult psychotic-like experiences. Br J Psychiatry 2011; 199: 38-42.
41. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, American Psychiatric Publishing, 2000, p 943.
42. Spitzer RL, Williams JB, Gibbon M, First MB: The Structured Clinical Interview for DSMIII-R (SCID). I. History, rationale, and description. Arch Gen Psychiatry 1992; 49: 624-629.
43. Williams JB, Gibbon M, First MB, Spitzer RL, Davies M, Borus J, et al: The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability. Arch Gen Psychiatry 1992; 49: 630-636.
44. Lee JW, Brown ES, Perantie DC, Bobadilla L: A comparison of Single-Item Visual Analog Scales with a multiitem Likert-type scale for assessment of cocaine craving in persons with bipolar disorder. Addict Disord Their Treat 2002; 1: 140-142.
45. Tiffany ST, Singleton E, Haertzen CA, Henningfield JE: The development of a cocainecraving questionnaire. Drug Alcohol Depend 1993; 34: 19-28.
46. Kampman KM, Volpicelli JR, McGinnis DE, Alterman AI, Weinrieb RM, D'Angelo L, et al: Reliability and validity of the Cocaine Selective Severity Assessment. Addict Behav 1998; 23: 449-461.
47. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA: Manual for the State-Trait Anxiety Inventory. Palo Alto, Consulting Psychologists' Press, 1983.
48. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571.
49. Corominas-Roso M, Roncero C, Eiroa-Orosa FJ, Gonzalvo B, Grau-Lopez L, Ribases M, et al: Brain-derived neurotrophic factor serum levels in cocaine-dependent patients during early abstinence. Eur Neuropsychopharmacol, doi: 10.1016/j.euroneuro.2012.08.016.
50. Grimm JW, Lu L, Hayashi T, Hope BT, Su T-P, Shaham Y: Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci 2003; 23: 742-747.
51. Graham DL, Edwards S, Bachtell RK, DiLeone RJ, Rios M, Self DW: Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-administration and relapse. Nat Neurosci 2007; 10: 1029-1037.
52. Fumagalli F, Moro F, Caffino L, Orrù A, Cassina C, Giannotti G, et al: Region-specific effects on BDNF expression after contingent or non-contingent cocaine i.v. self-administration in rats. Int J Neuropsychopharmacol 2013;16:913-918.
53. D'Sa C, Fox HC, Hong AK, Dileone RJ, Sinha R: Increased serum brain-derived neurotrophic factor is predictive of cocaine relapse outcomes: a prospective study. Biol Psychiatry 2011; 70: 706-711.
54. Thoenen H: Neurotrophins and neuronal plasticity. Science 1995; 270: 593-598.
55. Poo MM: Neurotrophins as synaptic modulators. Nat Rev Neurosci 2001; 2: 24-32.
56. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al: The BDNF Val66Met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257-269.
57. Fritsch B, Reis J, Martinowich K, Schambra HM, Ji Y, Cohen LG, et al: Direct current stimulation promotes BDNF-dependent synaptic plasticity: potential implications for motor learning. Neuron 2011; 66: 198-204.
58. Corominas M, Roncero C, Ribases M, Castells X, Casas M: Brain-derived neurotrophic factor and its intracellular signaling pathways in cocaine addiction. Neuropsychobiology 2007; 55: 2-13.
59. Costa MS, Botton PH, Mioranzza S, Ardais AP, Moreira JD, Souza DO, et al: Caffeine improves adult mice performance in the object recognition task and increases BDNF and TrkB independent on phospho-CREB immunocontent in the hippocampus. Neurochem Int 2008; 53: 89-94.
60. Alhaider IA, Aleisa AM, Tran TT, Alkadhi KA: Sleep deprivation prevents stimulationinduced increases of levels of P-CREB and BDNF: protection by caffeine. Mol Cell Neurosci 2011; 46: 742-751.
61. Tan YL, Zhou DF, Cao LY, Zou YZ, Zhang XY: Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett 2005; 382: 27-32.
62. Fujimura H, Altar CA, Chen R, Nakamura T, Nakahashi T, Kambayashi J, et al: Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 2002; 87: 728-734.
63. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ: Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998; 37: 1553-1561.
64. Karege F, Schwald M, Cisse M: Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002; 328: 261-264.
65. Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, et al: Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 2011; 14: 347-353.
66. Sartorius A, Hellweg R, Litzke J, Vogt M, Dormann C, Vollmayr B, et al: Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 2009; 42: 270-276.
67. Pillai A, Kale A, Joshi S, Naphade N, Raju MS, Nasrallah H, et al: Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol 2010; 13: 535-539.
68. Linnarsson S, Willson CA, Ernfors P: Cell death in regenerating populations of neurons in BDNF mutant mice. Brain Res Mol Brain Res 2000; 75: 61-69.
69. Poo MM: Neurotrophins as synaptic modulators. Nat Rev Neurosci 2001; 2: 24-32.
70. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al: The BDNF Val66Met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257-269.
71. Bramham CR, Messaoudi E: BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog Neurobiol 2005; 76: 99-125.
72. Karlsgodt KH, Sun D, Jimenez AM, Lutkenhoff ES, Willhite R, Van Erp TG, et al: Developmental disruptions in neural connectivity in the pathophysiology of schizophrenia. Dev Psychopathol 2008; 20: 1297-1327.
73. Pantelis C, Yücel M, Wood SJ, McGorry PD, Velakoulis D: Early and late neurodevelopmental disturbances in schizophrenia and their functional consequences. Aust NZJ Psychiatry 2003; 37: 399-406.
74. Bartlett TE, Wang YT: Illuminating synapsespecific homeostatic plasticity. Neuron 2011; 72: 682-685.
75. Chandler B, Grossberg S: Joining distributed pattern processing and homeostatic plasticity in recurrent on-center off-surround shunting networks: noise, saturation, short-term memory, synaptic scaling, and BDNF. Neural Netw 2012; 25: 21-29.
76. Desai NS, Rutherford LC, Turrigiano GG: BDNF regulates the intrinsic excitability of cortical neurons. Learn Mem 1999; 6: 284-291.
77. Rutherford LC, Nelson SB, Turrigiano GG: BDNF has opposite effects on the quantal amplitude of pyramidal neuron and interneuron excitatory synapses. Neuron 1998; 21: 521-530.
78. Turrigiano G: Homeostatic signaling: the positive side of negative feedback. Curr Opin Neurobiol 2007; 17: 318-324.
79. Balkowiec A, Katz DM: Activity-dependent release of endogenous brain-derived neurotrophic factor from primary sensory neurons detected by ELISA in situ. J Neurosci 2000; 20: 7417-7423.
80. McAllister AK, Katz LC, Lo DC: Neurotrophin regulation of cortical dendritic growth requires activity. Neuron 1996; 17: 1057-1064.
81. Nestler EJ: Is there a common molecular pathway for addiction? Nat Neurosci 2005; 8: 1445-1449.
82. Helmus TC, Downey KK, Wang LM, Rhodes GL, Schuster CR: The relationship between self-reported cocaine withdrawal symptoms and history of depression. Addict Behav 2001; 26: 461-467.
83. Nestler EJ: Molecular mechanisms of opiate and cocaine addiction. Curr Opin Neurobiol 1997; 7: 713-719.
84. Baumann MH, Rothman RB: Alterations in serotonergic responsiveness during cocaine withdrawal in rats: similarities to major depression in humans. Biol Psychiatry 1998; 44: 578-591.
85. Duman RS: Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med 2004; 5: 11-25.
86. Hashimoto K: BDNF variant linked to anxiety-related behaviors. Bioessays 2007; 29: 116-119.
87. Oral E, Canpolat S, Yildirim S, Gulec M, Aliyev E, Aydin N: Cognitive functions and serum levels of brain-derived neurotrophic factor in patients with major depressive disorder. Brain Res Bull 2012; 88: 454-459.
88. Gonul AS, Akdeniz F, Taneli F, Donat O, Eker C, Vahip S: Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci 2005; 255: 381-386.